HALIFAX, July 3 /CNW/ - Origin BioMed Inc., a manufacturer of over-the-counter topical drug products, announced today it has secured $3.8 million in funding, led by Calgary-based Avrio Ventures, along with co-investors Nova Scotia Business Inc. (NSBI) Venture Capital and several private individuals. This new investment will help drive the company’s North American market expansion, placing Origin’s leading diabetic neuropathy products - including Neuragen(R), a topical oil for fast-acting relief of diabetic foot pain - on American drug store shelves. Origin will also open a US office as part of this expansion.
